In a 78-year-old male post‑hip replacement with depression, anorexia, and weight loss, which antidepressant—fluoxetine, duloxetine, or bupropion—is most appropriate?

Bupropion is the Most Appropriate Choice for This Patient

For a 78-year-old male with post-hip replacement depression, anorexia, and weight loss, bupropion is the preferred antidepressant among the three options. Fluoxetine and duloxetine both carry significant risks of worsening anorexia and weight loss, which are already problematic in this patient, while bupropion has a more neutral weight profile and may even be considered for weight management in certain contexts.

Rationale for Avoiding Fluoxetine

Fluoxetine poses substantial risks in this clinical scenario:

• Weight Loss and Anorexia: The FDA label explicitly warns that "significant weight loss, especially in underweight depressed patients may be an undesirable result of treatment with Prozac" 1. In placebo-controlled trials, 11% of patients on fluoxetine reported anorexia versus 2% on placebo, with weight loss occurring in 1.4% versus 0.5% 1.

• Poor Evidence in Anorexia/Weight Loss States: Research specifically examining fluoxetine in patients with anorexia nervosa found no benefit. A randomized controlled trial of 93 patients showed fluoxetine failed to demonstrate any benefit in maintaining weight or preventing relapse after weight restoration (26.5% completion rate vs 31.5% placebo, p=0.57) 2. The only subgroup showing potential benefit was those with moderate-to-severe depression (BDI >20), where fluoxetine reduced relapse risk 3.

• Long Half-Life Complications: Fluoxetine's extended elimination half-life means "changes in dose will not be fully reflected in plasma for several weeks," complicating dose adjustments in an elderly post-surgical patient 1.

Rationale for Avoiding Duloxetine

While duloxetine has demonstrated safety in elderly patients with depression 4, it presents concerning issues for this specific patient:

• Weight Loss Profile: In the elderly safety study, duloxetine caused significant weight loss compared to placebo (-0.73 kg vs -0.13 kg, p=0.009) 4. This is unacceptable in a patient already experiencing anorexia and weight loss.

• Comparative Suicide Risk in Adolescents: Though this patient is elderly, recent data in female adolescents showed higher suicide attempt rates with duloxetine compared to bupropion 5, raising safety concerns about duloxetine's risk-benefit profile in vulnerable populations.

• Nausea and GI Effects: Duloxetine's most common adverse effect is nausea 6, which could further compromise nutritional intake in a patient with existing anorexia.

Why Bupropion is Preferred

Bupropion offers the most favorable profile for this patient's specific constellation of symptoms:

Weight and Appetite Advantages

• Weight-Neutral to Positive: Bupropion is FDA-approved as a component of weight management medications 7, 8. While monotherapy has "weak anorectic effects" 8, it does not carry the same weight loss warnings as SSRIs. The obesity management guidelines note bupropion "activates proopiomelanocortin neurons in the hypothalamus" but this effect is substantially mitigated without naltrexone 8.

• Clinical Context: The guideline specifically states "it is reasonable to prioritize naltrexone-bupropion ER for appropriate patients with depressed mood" 8, and notes that "bupropion is FDA-approved as an antidepressant. At 300 mg daily...bupropion has been shown to be effective for the long-term treatment of recurrent major depression" 8.

Efficacy in Elderly Depression

• Proven Efficacy: A head-to-head trial in elderly outpatients (≥60 years, range 60-88) comparing bupropion SR (100-300 mg/day) with paroxetine showed equivalent efficacy on HAM-D scores, with both groups demonstrating improved depression ratings 9.

• Favorable Side Effect Profile: The study concluded "because of its favorable side effect profile, bupropion SR may provide a safe and effective nonserotonergic treatment alternative that is well suited as an antidepressant for the elderly" 9.

• Expert Consensus: The 2001 expert consensus guidelines on geriatric depression, while rating SSRIs highest overall, acknowledged bupropion as a viable first-line option 10.

Safety Considerations in This Patient

• Post-Surgical Context: The patient is post-hip replacement. If opioid analgesia is still needed or anticipated for rehabilitation-related pain, bupropion does not interfere with opioid efficacy (unlike naltrexone-bupropion combinations which are contraindicated) 8.

• Cardiovascular Profile: In the elderly comparison trial, "no statistically significant differences between groups in vital signs or weight were found" between bupropion and paroxetine 9.

• Seizure Risk: While bupropion lowers seizure threshold 11, this risk is dose-dependent and manageable with appropriate dosing (avoid exceeding 450 mg/day) 7. There is no indication this patient has epilepsy or other seizure risk factors.

Practical Prescribing Approach

Initiate bupropion SR 150 mg once daily in the morning 7. After one week, if tolerated, increase to 150 mg twice daily (total 300 mg/day). The sustained-release formulation is preferred in elderly patients for better tolerability 9.

Monitor for:

• Blood pressure (bupropion can cause modest increases) 11
• Insomnia (dose second tablet no later than mid-afternoon) 7
• Agitation or anxiety (occurred in >10% in elderly trials but was not significantly different from paroxetine) 9

Avoid bupropion if:

• History of seizure disorder or conditions that lower seizure threshold 11
• Current use or recent discontinuation (<14 days) of MAOIs 11
• Eating disorder diagnosis (though this patient has anorexia as a symptom of depression, not anorexia nervosa) 7

Common Pitfalls to Avoid

1. Don't reflexively choose an SSRI: While SSRIs like sertraline and citalopram received highest expert ratings for geriatric depression generally 10, they are inappropriate when anorexia and weight loss are prominent features.

2. Don't use fluoxetine for "appetite stimulation": Despite occasional clinical lore, fluoxetine consistently causes weight loss and anorexia 1, 2.

3. Don't combine with naltrexone: While naltrexone-bupropion is effective for weight management and depression 8, it would be contraindicated if post-surgical opioid use is needed 8.

4. Don't exceed maximum doses: Bupropion should not exceed 450 mg/day due to seizure risk 7, 11. In elderly patients with renal impairment, dose reduction may be necessary.

The evidence strongly supports bupropion as the safest and most appropriate choice among these three options for a 78-year-old male with depression, anorexia, and weight loss following hip replacement.